Clinical trials

Aim of the study was to compare physically active women with and without Polyendocrine Metabolic Ovarian Syndrome (PMOS) in terms of core stability, body awareness, pelvic health, sleep, and quality of life, and to reveal the possible effects of the presence of PMOS on these parameters despite physical activity.

Aim of the study is to compare the levels of spinal stabilization, posture, deep neck flexor muscle endurance, and body awareness of physiotherapy and rehabilitation students and architecture students, whose academic training processes and professional practices are different but intensive, and who possess different physical usage characteristics in these processes, and to reveal the effects of professional training content on the musculoskeletal system.

Aim of the study is to examine the impact of a history of hamstring injury on athletes by determining and comparing the pre- and post-training levels of sprint performance, agility, dynamic balance, and body awareness in football players with and without a history of hamstring injury.

Aim of the study is to evaluate upper extremity performance between wheelchair para-armwrestling and para-archery athletes in a multidimensional way and to compare upper extremity reaction time, body awareness, grip strength, agility, and functionality parameters.

Aim of the study is to compare balance, core stabilization performance, foot reaction time, and body awareness in 50 amateur football players aged 13-19 (Group I: 13-15 years, and Group II: 16-19 years) according to age, and to determine age-related performance differences.

The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in patients with relapsed/refractory B-cell malignancies, including B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma. The study is supported by the Presidency of Turkish Health Institutes (TÜSEB) and will be conducted at four centers. This therapy is based on collecting the patient's own T cells, genetically modifying them in a laboratory to recognize the CD19 antigen, and reinfusing them into the patient. The goal is to target leukemia or lymphoma cells and achieve disease control. The primary objective is to assess the overall response rate at Day 28 after infusion and to evaluate the safety profile of the treatment. Secondary objectives include assessment of complete response rate, duration of response, overall survival, and progression-free survival, as well as the frequency and severity of cytokine release syndrome (CRS), neurotoxicity (ICANS), and other treatment-related adverse events. In addition, the in vivo persistence and immunological effects of CAR-T cells will be evaluated. Eligible patients must be 18 years of age or older, have an adequate performance status, sufficient organ function, and meet disease-specific eligibility criteria. Key exclusion criteria include active severe infection, uncontrolled cardiac disease, active central nervous system involvement (where applicable), HIV or active hepatitis infection, pregnancy, and severe immunodeficiency. The treatment process includes leukapheresis for cell collection, administration of lymphodepleting chemotherapy if required, followed by a single infusion of CAR-T cells. Patients will be closely monitored after infusion, particularly during the early period, and both early and late adverse events, as well as treatment response, will be regularly assessed. A total of 40 patients are planned to be enrolled. The overall clinical follow-up period, including short- and long-term monitoring, is expected to last approximately 30 months. Data will be analyzed using appropriate statistical methods.